Chromaderm, Inc.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 685
- Registration Number
- NCT00604383
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00552227
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States
Effect of LY333531 on Vascular and Neural Functions
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00482976
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00297401
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada
Treatment for Completers of the Study B7A-MC-MBCM
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT00266695
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Madison, Wisconsin, United States
- Prev
- 1
- 2
- Next